168267-86-5

Basic information

• Product Name: 2-methoxy-5-(tetrazol-1-yl)-benzoic acid,methyl ester
• Synonyms: 2-methoxy-5-(tetrazol-1-yl)-benzoic acid,methyl ester
• CAS NO: 168267-86-5
• Molecular Weight: 234.214
• Mol File: 168267-86-5.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: 2-methoxy-5-(tetrazol-1-yl)-benzoic acid,methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-methoxy-5-(tetrazol-1-yl)-benzoic acid,methyl ester(168267-86-5)
• EPA Substance Registry System: 2-methoxy-5-(tetrazol-1-yl)-benzoic acid,methyl ester(168267-86-5)

Safety Data

• Hazardous Substances Data: 168267-86-5(Hazardous Substances Data)

Upstream product

• 34841-11-7 methyl 2-methoxy-5-nitrobenzoate 
• 96-97-9 5-nitrosalicylic acid 
• 22802-67-1 methyl 2-methoxy-5-aminobenzoate 
• 122-51-0 orthoformic acid triethyl ester 

Downstream Products

• 191604-61-2 2-methoxy-5-(1H-tetrazol-1-yl)benzoyl chloride 
• 235098-06-3 (S)-N-methyl-N-(2-phenylpent-4-enyl)-2-methoxy-5-(1H-tetrazol-1-yl)-benzamide 
• 191604-76-9 2-methoxy-5-(5-N,N-dimethylaminomethyl-1H-tetrazol-1-yl)benzoic acid 
• 370559-55-0 methyl 2-methoxy-5-(5-N,N-dimethylaminomethyl-1H-tetrazol-1-yl)benzoate 
• 195622-35-6 2-methoxy-5-(1H-tetrazol-1-yl)benzoic acid 

Relevant articles and documents

CARBOXY SUBSTITUTED CARBOXAMIDE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS

-

SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL)[1,4]DIAZEPANES USEFUL FOR THE TREATMENT ALLERGIC DISEASES

The present invention relates to novel 4-(1H-benzimidazol-2-yl)[1,4] diazepane derivatives of formula (1): and stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonist. Such antagonists are useful in the treatment of allergic rhinitis, including seasonal rhinitis and sinusitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; asthma; bronchitis; and emesis.

Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease

The present invention relates to novel 4-(1H-benzimidazol-2-yl)[1,4]diazepane derivatives of formula (1): and stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonist. Such antagonists are useful in the treatment of allergic rhinitis, including seasonal rhinitis and sinusitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; asthma; bronchitis; and emesis.